openPR Logo
Press release

Acute Pain Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

05-01-2025 08:22 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Acute Pain Clinical Trials and Studies 2025: EMA, PDMA, FDA

DelveInsight's, "Acute Pain Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Pain Research. Learn more about our innovative pipeline today! @ Acute Pain Pipeline Outlook [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute Pain Pipeline Report

* In April 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectomy.
* In April 2025, Latigo Biotherapeutics conducted a phase 2 dose-ranging study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars.
* DelveInsight's Acute Pain Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Pain treatment.
* The leading Acute Pain Companies such as Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc . and others.
* Promising Acute Pain Pipeline Therapies such as Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.

Stay informed about the cutting-edge advancements in Acute Pain treatments. Download for updates and be a part of the revolution in neurology care @ Acute Pain Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acute Pain Emerging Drugs Profile

* NTM-001: Neumentum

NTM-001 is Neumentum's lead product candidate: a novel, alcohol-free formulation of the powerful NSAID ketorolac, in a pre-mixed bag designed for 24-hours of continuous infusion following surgery. It is being evaluated to manage moderately severe acute pain that requires analgesia at the opioid-level, usually in a postoperative setting.

* CGT 1507: CGeneTech

Otenaproxesul is a novel nonsteroidal anti-inflammatory drug ("NSAID") that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications. Otenaproxesul, is being developed as a safer non-opioid analgesic for post-operative pain.

* TRPA1 Antagonist: Algomedix

Algomedix is developing a non-opioid, non-addictive, novel TRPA1 antagonist for the treatment of acute and chronic pain. Algomedix is focused on the advancement of a novel, small molecule TRPA1 antagonist for the treatment of pain. This clinical candidate offers the potential for a next-generation analgesic devoid of the addiction and abuse liabilities, as well as other adverse effects inherent in the opioid class of drugs.

Acute Pain Market Drivers

* Increasing demand for long-term pain management among the geriatric population
* Government investments for healthcare interoperability

Acute Pain Market Barriers

* The availability of alternate pain management systems
* Side-effects associated with the disease

Learn more about Acute Pain Drugs Opportunities in our groundbreaking Acute Pain Research and development projects @ Acute Pain Unmet Needs [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Acute Pain pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Acute Pain with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Pain Treatment.
* Acute Pain Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acute Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Pain market.

Acute Pain Companies

Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc . and others

Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Acute Pain Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Acute Pain treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ Acute Pain Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Acute Pain Pipeline Report

* Coverage- Global
* Acute Pain Companies- Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures, Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, and Scilex Pharmaceuticals, Inc. and others.
* Acute Pain Pipeline Therapies- Methoxyflurane 3mL, Methoxyflurane, S-Ibuprofen, VX-993, HB/APAP, Cebranopadol, Oxycodone IR, Suzetrigine, VX-548, PF614 and others.
* Acute Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acute Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase II

For a detailed overview of our latest research findings and future plans, read the full details of Acute Pain Pipeline on our website @ Acute Pain Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/acute-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Acute Pain: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acute Pain- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NTM-001: Neumentum
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* TRPA1 Antagonist: Algomedix
* Drug profiles in the detailed report.....
* Inactive Products
* Acute Pain Key Companies
* Acute Pain Key Products
* Acute Pain- Unmet Needs
* Acute Pain- Market Drivers and Barriers
* Acute Pain- Future Perspectives and Conclusion
* Acute Pain Analyst Views
* Acute Pain Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-pain-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-pain-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Pain Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here

News-ID: 3996178 • Views:

More Releases from ABNewswire

Improving Social Skills and Communication: Flywheel Centers Details the Benefits of ABA Therapy for Autism in Charlotte, NC
Improving Social Skills and Communication: Flywheel Centers Details the Benefits …
Flywheel Centers explains how ABA therapy improves social skills and communication in children with autism in Charlotte, NC, offering personalized support for growth. Charlotte, NC - Autism Spectrum Disorder (ASD) is a developmental condition that affects how individuals communicate, interact, and process information. For families in Charlotte, NC, seeking effective therapies to support their loved ones with autism, Applied Behavior Analysis (ABA) therapy has proven to be a valuable tool. ABA
Stellar Scientific Explains Why Gravity Convection Ovens Are Perfect for Delicate and Consistent Heating
Stellar Scientific Explains Why Gravity Convection Ovens Are Perfect for Delicat …
Stellar Scientific explains how gravity convection ovens ensure consistent and delicate heating, making them perfect for precision cooking in various industries. In laboratory and industrial environments, precision and consistency are crucial when it comes to heating applications. Whether it's for drying, sterilizing, or sample preparation, a stable and uniform heat distribution ensures accurate results. Gravity convection ovens, known for their reliability and delicate temperature control, are an ideal solution for such
Unlocking Potential with ABA Therapy: How A Gem of Joy ABA Helps Children with Autism in Baltimore, MD
Unlocking Potential with ABA Therapy: How A Gem of Joy ABA Helps Children with A …
A Gem of Joy ABA in Baltimore, MD, uses ABA therapy to unlock potential in children with autism, helping them develop key skills for a brighter future. Baltimore, MD - Autism Spectrum Disorder (ASD) affects millions of children worldwide, presenting unique challenges in communication, behavior, and social interaction. For families in Baltimore, MD, finding effective therapies is essential in helping children with autism reach their full potential. A Gem of Joy
The Healing Power of Art: How Creative Therapy Zone in Thornhill, ON, Uses Art Therapy for Mental Wellness
The Healing Power of Art: How Creative Therapy Zone in Thornhill, ON, Uses Art T …
Creative Therapy Zone in Thornhill, ON, harnesses the healing power of art therapy, helping individuals improve mental wellness through creative expression and support. Thornhill, ON - Mental wellness is an essential aspect of overall health, and individuals facing mental health challenges often seek therapeutic approaches that go beyond traditional talk therapy. Art therapy has emerged as a powerful tool for individuals looking to express themselves, process emotions, and heal through creativity.

All 5 Releases


More Releases for Acute

Acute Lymphoblastic Leukemia Therapeutics Market Size, Acute Lymphoblastic Leuke …
Acute Lymphoblastic Leukemia Therapeutics Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Acute Lymphoblastic Leukemia Therapeutics research data, benefit, gross margin,
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H …
ReportsWorldwide has announced the addition of a new report title Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Renal Failure (ARF) (Acute Kidney Injury) clinical trials scenario. This report provides top line data relating to
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Tri …
ReportsWorldwide has announced the addition of a new report title Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth